Phase I/II study (NCT02885766) of this agent is recruiting patients with Ph‐positive CML whose disease is resistant to the second‐generation ABL1 inhibitors or has T315I mutation in the BCR–ABL gene. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.